Publicaciones científicas

Identification of coding and long non-coding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues

Unfried JP (1), Serrano G (2), Suárez B (1), Sangro P (3), Ferretti V (1), Prior C (4), Boix L (5), Bruix J (5), Sangro B (6), Segura V (7), Fortes P (8).

(1) Division of Gene Therapy and Hepatology, Foundation for Applied Medical Research.
(2) Bioinformatics Platform, Foundation for Applied Medical Research.
(3) Liver Unit, Clínica Universidad de Navarra.
(4) Division of Oncology, CIMA, University of Navarra.
(5) BCLC group, Hospital Clinic-IDIBAPS and CIBEREHD.
(6) Liver Unit, Clínica Universidad de Navarra-IDISNA and CIBEREHD.
(7) Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), and University Clinic, University of Navarra.
(8) Division of Gene Therapy and Hepatology, CIMA, IDISNA

Revista: Cancer Research

Fecha: 06-ago-2019

Hepatología

RESUMEN

The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets allow unprecedented gene expression analyses.

Here, using these datasets we performed pan-cancer and pan-tissue identification of coding and long non-coding RNA (lncRNAs) transcripts differentially expressed in tumors and preferentially expressed in healthy tissues and/or tumors. Pan-cancer comparison of mRNAs and lncRNAs showed that lncRNAs were deregulated in a more tumor-specific manner.

Given that lncRNAs are more tissue-specific than mRNAs, we identified healthy tissues that preferentially express lncRNAs upregulated in tumors and found that testis, brain, the digestive tract and blood/spleen were the most prevalent. In addition, specific tumors also upregulate lncRNAs preferentially expressed in other tissues, generating a unique signature for each tumor type.

Most tumors studied downregulated lncRNAs preferentially expressed in their tissue of origin, probably as a result of de-differentiation. However, the same lncRNAs could be upregulated in other tumors resulting in "bimorphic" transcripts. In hepatocellular carcinoma (HCC), the upregulated genes identified were expressed at higher levels in patients with worse prognosis.

Some lncRNAs upregulated in HCC and preferentially expressed in healthy testis or brain were predicted to function as oncogenes and were significantly associated with higher tumor burden, and poor prognosis, suggesting their relevance in hepatocarcinogenesis and/or tumor evolution.

Taken together, therapies targeting oncogenic lncRNAs should take into consideration the healthy tissue where the lncRNAs are preferentially expressed, to predict and decrease unwanted secondary effects and increase potency.

CITA DEL ARTÍCULO  Cancer Res. 2019 Aug 6. pii: canres.0400.2019. doi: 10.1158/0008-5472.CAN-19-0400

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra